Siemens to distribute Calypso in EU

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Calypso Medical Technologies, a developer of real-time localization technology used for the tracking of tumor targets, has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.

Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years, according to the Seattle-based Calypso.

Last year, Calypso entered into a master development agreement with Siemens to jointly develop products integrating the Calypso System with the Siemens Artiste linear accelerator and other Siemens radiotherapy technologies.

 

Justine Varieur Cadet

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.